| Literature DB >> 20011114 |
Sasisekhar Bennuru1, Thomas B Nutman.
Abstract
Even in the absence of an adaptive immune system in murine models, lymphatic dilatation and dysfunction occur in filarial infections, although severe irreversible lymphedema and elephantiasis appears to require an intact adaptive immune response in human infections. To address how filarial parasites and their antigens influence the lymphatics directly, human lymphatic endothelial cells were exposed to filarial antigens, live parasites, or infected patient serum. Live filarial parasites or filarial antigens induced both significant LEC proliferation and differentiation into tube-like structures in vitro. Moreover, serum from patently infected (microfilaria positive) patients and those with longstanding chronic lymphatic obstruction induced significantly increased LEC proliferation compared to sera from uninfected individuals. Differentiation of LEC into tube-like networks was found to be associated with significantly increased levels of matrix metalloproteases and inhibition of their TIMP inhibitors (Tissue inhibitors of matrix metalloproteases). Comparison of global gene expression induced by live parasites in LEC to parasite-unexposed LEC demonstrated that filarial parasites altered the expression of those genes involved in cellular organization and development as well as those associated with junction adherence pathways that in turn decreased trans-endothelial transport as assessed by FITC-Dextran. The data suggest that filarial parasites directly induce lymphangiogenesis and lymphatic differentiation and provide insight into the mechanisms underlying the pathology seen in lymphatic filariasis.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20011114 PMCID: PMC2781552 DOI: 10.1371/journal.ppat.1000688
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1Filarial antigen-induced proliferation.
LEC at 5×103 were seeded in 96-well tissue culture plates in endothelial basal media and stimulated with optimized concentrations (10 µg/ml) of BmA, BmMAg, MfAg, and VEGF (25 ng/ml or 10ng/ml). Data are expressed as stimulation index over the unstimulated controls for each set of cultures and the horizontal bar is the geometric mean. Panels A and B show the response of LEC (Panel A) and HUVEC (Panel B) to the stimuli shown on the x-axis. Panels C and D show the proliferative effect on HUVEC and LEC of schistosome egg antigen (SEA Panel C) and of schistosome adult antigen (SWAP Panel D).
Figure 2Filarial serum/plasma induced proliferation.
LEC cultured with 1% pooled plasma from different patient groups (EN, MF, CP, AB) and proliferation measured by uptake of BrDU at 96 h. Data are expressed as relative luminescence units (rLu) over media controls and are expressed as the mean (+95% CI).
Figure 3Microscopic images of filaria-induced lymphatic tube-like structure formation.
LEC were seeded in endothelial basal media (Panels A and E) and stimulated with BmA (B), BmMAg (C), and MfAg (D), live microfilariae (F), live adult males (H), adult females (J) in contact or in transwells with live microfilariae (G), adult males (I), or adult females (K). (Magnification 20× (Panels A–D), 40× (Panels E–K)).
Figure 4Expression of lymphangiogenic markers upon stimulation with MfAg by LEC as assessed by qRT-PCR.
Data are expressed as the mean (+95% CI) fold change from unstimulated controls of 4 independent experiments.
List of MfAg induced 2-fold upregulated genes.
| Name | Description | Fold Change |
| CADM1 | cell adhesion molecule 1 | 12.295 |
| TBK1 | TANK-binding kinase 1 | 8.664 |
| RBP7 | retinol binding protein 7, cellular | 7.346 |
| GJA4 | gap junction protein, alpha 4, 37kDa | 7.341 |
| ADFP | adipose differentiation-related protein | 7.321 |
| CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 | 6.788 |
| PLTP | phospholipid transfer protein | 6.727 |
| CASK | calcium/calmodulin-dependent serine protein kinase (MAGUK family) | 6.476 |
| ANGPTL4 | angiopoietin-like 4 | 6.422 |
| CD36 | CD36 molecule (thrombospondin receptor) | 6.16 |
| TGFBI | transforming growth factor, beta-induced, 68kDa | 5.93 |
| ENC1 | ectodermal-neural cortex (with BTB-like domain) | 5.844 |
| ACSL1 | acyl-CoA synthetase long-chain family member 1 | 5.641 |
| C19ORF2 | chromosome 19 open reading frame 2 | 5.468 |
| GUSB | glucuronidase, beta | 4.897 |
| IQGAP2 | IQ motif containing GTPase activating protein 2 | 4.857 |
| FAM14A | family with sequence similarity 14, member A | 4.646 |
| GUCY1A3 | guanylate cyclase 1, soluble, alpha 3 | 4.643 |
| MMP1 | matrix metallopeptidase 1 (interstitial collagenase) | 4.624 |
| HDAC5 | histone deacetylase 5 | 4.563 |
| KIF21A | kinesin family member 21A | 4.547 |
| RPESP | RPE-spondin | 4.525 |
| SYT9 | synaptotagmin IX | 4.359 |
| IL1R1 | interleukin 1 receptor, type I | 4.332 |
| PDK4 | pyruvate dehydrogenase kinase, isozyme 4 | 4.305 |
| NP | nucleoside phosphorylase | 4.305 |
| NNMT | nicotinamide N-methyltransferase | 4.263 |
| GADD45G | growth arrest and DNA-damage-inducible, gamma | 4.26 |
| FAM46A | family with sequence similarity 46, member A | 4.249 |
| CREB5 | cAMP responsive element binding protein 5 | 4.216 |
| UCHL1 | ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) | 4.158 |
| CH25H | cholesterol 25-hydroxylase | 4.05 |
| 6-Sep | septin 6 | 4.045 |
| VIP | vasoactive intestinal peptide | 4.008 |
| ATP5G2 | ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C2 (subunit 9) | 3.994 |
| CECR1 | cat eye syndrome chromosome region, candidate 1 | 3.992 |
| CIB1 | calcium and integrin binding 1 (calmyrin) | 3.853 |
| ICAM2 | intercellular adhesion molecule 2 | 3.818 |
| RPS9 | ribosomal protein S9 | 3.816 |
| AKR1C2 | aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) | 3.813 |
| BCL11A | B-cell CLL/lymphoma 11A (zinc finger protein) | 3.766 |
| PLA2R1 | phospholipase A2 receptor 1, 180kDa | 3.735 |
| CLDN23 | claudin 23 | 3.727 |
| PRELID1 | PRELI domain containing 1 | 3.678 |
| FECH | ferrochelatase (protoporphyria) | 3.671 |
| OAS1 | 2′,5′-oligoadenylate synthetase 1, 40/46kDa | 3.671 |
| MYL6B | myosin, light chain 6B, alkali, smooth muscle and non-muscle | 3.638 |
| GDF15 | growth differentiation factor 15 | 3.638 |
| FLOT1 | flotillin 1 | 3.63 |
| ACADVL | acyl-Coenzyme A dehydrogenase, very long chain | 3.613 |
| ZNF197 | zinc finger protein 197 | 3.573 |
| RPL18A | ribosomal protein L18a | 3.497 |
| KIAA1271 | virus-induced signaling adapter | 3.492 |
| ATP8A1 | ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 | 3.482 |
| TSKU | tsukushin | 3.463 |
| HMOX1 | heme oxygenase (decycling) 1 | 3.449 |
| ID4 | inhibitor of DNA binding 4, dominant negative helix-loop-helix protein | 3.378 |
| ALDH2 | aldehyde dehydrogenase 2 family (mitochondrial) | 3.359 |
| MCTS1(includesEG:28985) | malignant T cell amplified sequence 1 | 3.338 |
| HERC5 | hect domain and RLD 5 | 3.26 |
| SPTBN1 | spectrin, beta, non-erythrocytic 1 | 3.211 |
| CHST3 | carbohydrate (chondroitin 6) sulfotransferase 3 | 3.134 |
| INHBB | inhibin, beta B | 3.125 |
| DYRK2 | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 | 3.108 |
| PAG1 | phosphoprotein associated with glycosphingolipid microdomains 1 | 2.988 |
| MGC11324 | lung cancer metastasis-associated protein | 2.961 |
| MGMT | O-6-methylguanine-DNA methyltransferase | 2.946 |
| RHOU | ras homolog gene family, member U | 2.944 |
| MGLL | monoglyceride lipase | 2.944 |
| DCLRE1C | DNA cross-link repair 1C (PSO2 homolog, S. cerevisiae) | 2.912 |
| NOC2L | nucleolar complex associated 2 homolog (S. cerevisiae) | 2.902 |
List of MfAg induced 2-fold down-regulated genes.
| Name | Description | Fold Change |
| CTGF | connective tissue growth factor | 8.586 |
| ACTB | actin, beta | 8.129 |
| OLFML3 | olfactomedin-like 3 | 6.238 |
| SORBS2 | sorbin and SH3 domain containing 2 | 5.134 |
| PEG10 | paternally expressed 10 | 4.721 |
| IER3 | immediate early response 3 | 4.287 |
| RRM2 | ribonucleotide reductase M2 polypeptide | 4.095 |
| GJA1 | gap junction protein, alpha 1, 43kDa | 4.093 |
| RPL24 | ribosomal protein L24 | 4.056 |
| MARCKS | myristoylated alanine-rich protein kinase C substrate | 3.983 |
| SNCAIP (includes EG:9627) | synuclein, alpha interacting protein (synphilin) | 3.784 |
| GFRA1 | GDNF family receptor alpha 1 | 3.663 |
| SC4MOL | sterol-C4-methyl oxidase-like | 3.338 |
| DHCR24 | 24-dehydrocholesterol reductase | 3.31 |
| DDAH1 | dimethylarginine dimethylaminohydrolase 1 | 3.297 |
| ERBB4 | v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) | 3.285 |
| SEMA3C | sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C | 3.236 |
| GCNT1 | glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase) | 3.224 |
| USP21 | ubiquitin specific peptidase 21 | 3.123 |
| NEBL | nebulette | 3.055 |
| PLA2G4B | phospholipase A2, group IVB (cytosolic) | 2.979 |
| EPS15L1 | epidermal growth factor receptor pathway substrate 15-like 1 | 2.86 |
| NAPE-PLD | N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D | 2.678 |
| CASP4 | caspase 4, apoptosis-related cysteine peptidase | 2.519 |
Figure 5Expression of junction molecules by LEC by microarray analysis.
Shown in the heat map are the relative expression levels of the genes listed in response to BmA (B) or MfAg (M) at 24-, 48-, and 72-h time points. The control values (C) are the relative expression levels of pooled controls at the time-points listed. The heat map scale is shown in the inset.
Figure 6Filarial antigens induce metalloproteases MMP-1 and MMP-2.
Shown are the levels of TIMP-1 (Panel A) and TIMP-2 (Panel B), MMP-1 (Panel C) and MMP-2 (Panel D) upon stimulation with various filarial antigens. Data are expressed as the mean (+95% CI) % change from control (media) for 3 independent experiments.
Figure 7BmA and MfAg inhibit the TNF-α or IL-1α induced hyper-permeability of LEC monolayers.
Shown are the mean (+95% CI) relative fluorescence units of 4 independent permeability assays through LEC confluent monolayers.